Vaccine group announces creation of Ebola vaccine stockpile

Vaccine alliance announces creation of Ebola vaccine stockpile of about 500,000 doses
Source: ABC News: Health - Category: Consumer Health News Tags: Health Source Type: news

Related Links:

Dalhousie University professor Matthew Herder accessed hundreds of government documents to find out what really happened as Canadian scientists tried for years to get the pharmaceutical industry interested in their discovery of an Ebola vaccine.
Source: CBC | Health - Category: Consumer Health News Tags: News/Health Source Type: news
Condition:   Ebola Interventions:   Biological: Ad26.ZEBOV;   Biological: MVA-BN-Filo;   Biological: Placebo Sponsor:   Janssen Vaccines & Prevention B.V. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Source: National Institutes of Health (NIH). Published: 1/14/2020. This one-hour, 44-minute presentation discusses how the National Institutes of Health (NIH) has been at the forefront in the global effort to prevent the spread of Ebola virus. NIH staff were deployed in western Africa during the 2015-2016 Ebola outbreak to provide primary care to those infected, and Ebola patients were received at the NIH Clinical Center. For many years prior, NIH scientists studied the natural reservoirs of emerging viruses such as Ebola virus and have elucidated the biology of Ebola virus infection, which has informed the creation of in...
Source: Disaster Lit: Resource Guide for Disaster Medicine and Public Health - Category: International Medicine & Public Health Source Type: news
(INSERM (Institut national de la sant é et de la recherche m é dicale)) Public health efforts successfully stopped human-to-human transmission of Ebola virus in West Africa in 2016 after the worst Ebola outbreak in history. Pursuing and intensifying efforts to develop a safe and effective vaccination strategy against Ebola virus disease, with durable protection in all populations, including children, is vital.
Source: EurekAlert! - Infectious and Emerging Diseases - Category: Infectious Diseases Source Type: news
Publication date: Available online 10 January 2020Source: Antiviral ResearchAuthor(s): Elizabeth C. Clarke, Steven B. BradfuteAbstractFor more than 20 years, researchers have used laboratory mice lacking type I or both type I and type II interferon (IFN) responses to study viruses that cause hemorrhagic fever (HF) in humans. Whereas immunocompetent mice do not become ill when infected with Ebola, Lassa, dengue and other HF viruses, IFN-deficient mice typically develop severe or fatal disease when inoculated with these pathogens. The ease of employment of these “mouse models” has led to their extensive use in bi...
Source: Antiviral Therapy - Category: Virology Source Type: research
Abstract For more than 20 years, researchers have used laboratory mice lacking type I or both type I and type II interferon (IFN) responses to study viruses that cause hemorrhagic fever (HF) in humans. Whereas immunocompetent mice do not become ill when infected with Ebola, Lassa, dengue and other HF viruses, IFN-deficient mice typically develop severe or fatal disease when inoculated with these pathogens. The ease of employment of these "mouse models" has led to their extensive use in biocontainment laboratories to assess the efficacy of novel vaccines, often without consideration of whether adaptive im...
Source: Antiviral Research - Category: Virology Authors: Tags: Antiviral Res Source Type: research
[Deutsche Welle] The deadly virus has killed nearly three times as many people in the Democratic Republic of Congo as any Ebola outbreak. It's preventable with a vaccine.
Source: AllAfrica News: Health and Medicine - Category: African Health Source Type: news
(Natural News) An effort is under way right now to harvest Ebola-infected subjects from African nations, then transport them to the U.S. border and have them cross into the United States as “human weapons” who will unleash Ebola on U.S. soil. This is part of the globalist effort to bring down the United States of...
Source: NaturalNews.com - Category: Consumer Health News Source Type: news
Source: Chemical and Engineering News - Category: Chemistry Authors: Source Type: research
In this study, we generated recombinant baculoviruses (rBV) expressing the Sudan virus (SUDV) matrix structural protein (VP40) (rBV-VP40-VP40) or the SUDV glycoprotein (GP) (rBV-GP-GP), and SUDV virus-like particles (VLPs) were produced by co-infection of Sf9 cells with rBV-SUDV-VP40 and rBV-SUDV-GP. The expression of SUDV VP40 and GP in SUDV VLPs was demonstrated by IFA and Western blot analysis. Electron microscopy results demonstrated that SUDV VLPs had a filamentous morphology. The immunogenicity of SUDV VLPs produced in insect cells was evaluated by the immunization of mice. The analysis of antibody responses showed t...
Source: Viruses - Category: Virology Authors: Tags: Article Source Type: research
More News: Ebola | Ebola Vaccine | Health | Vaccines